eugenecj
8 years ago
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company") and LipimetiX Development, Inc., the Company's drug development joint venture ("JV") announced today that the JV's lead commercial drug candidate, AEM-28-14, showed substantial and statistically-significant LDL cholesterol (LDLc) reductions in a hypercholesterolemic primate study at Wake Forest University. Following a single IV administration of escalating doses up to 5mg/kg, LDLc exhibited a mean reduction of 64% from baseline at 24 hours, 46% from baseline at 3 days and 16% from baseline at 7 days, despite the study animals remaining on a high fat/cholesterol diet through the full study.
A PDF accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/065505f4-bc99-4efc-b76d-b7d16c876ed3
Dennis I. Goldberg, PhD, President and CEO of LipimetiX Development, Inc. stated "AEM-28-14 has shown clinically-relevant levels of cholesterol reduction in multiple validated preclinical models and may be the most powerful lipid reduction agent yet discovered. Primate models are often predictive of a molecule's therapeutic performance in humans. Accordingly, we see the LDLc reduction in this primate model as consistent with the benefits that we hope to deliver to Homozygous Familial Hypercholesterolemia (HoFH) patients...powerful cholesterol lowering combined with duration of effect."
The JV's development goals are to conduct Phase 1a, 1b, and 2a human clinical trials with AEM-28-14 to show an acceptable safety profile and cholesterol reduction efficacy in HoFH, an orphan genetic disease characterized by extremely high LDLc due to inherited defects in the LDL receptor pathway from both parents. The hypercholesterolemia associated with HoFH is difficult to treat since it is refractory to drugs and biologics, such as statins and PCSK9 inhibitors, that increase the expression and functionality of the LDL receptor in normal patients.
Chimeric Apolipoprotein E Mimetic Peptides
Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride-rich lipoproteins to specific receptors in the liver, decreasing these levels in the blood. Defective metabolism of cholesterol and triglyceride-rich lipoprotein remnants plays an important role in the development of diseases of the coronary, cerebral and peripheral arteries often leading to heart attack and stroke.
The University of Alabama at Birmingham ("UAB") scientists patented the first chimeric Apo E mimetic peptide in 1999, reducing the 299 amino acid native Apo E into a 28 amino acid, dual domain peptide that can be delivered therapeutically. One domain inserts into a lipoprotein surface and the second domain binds to the Apo E receptors in the liver. In 2010, our JV's founding scientist, Dr. Dennis Goldberg, obtained worldwide right to patents for Apo E mimetic peptides from the UAB Research Foundation ("UABRF"). The JV has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and its analogs.
The JV has continued research in to a new generation of chimeric Apo E peptides and has discovered AEM-28-14, resulting in a USPTO and PCT patent filing in 2015 supporting claims for a broad domain of Apo E mimetic peptides. AEM-28-14 was found to be more potent (as tested in multiple
stocktrademan
9 years ago
$CAPS recent news/filings
bullish
charts that are focused on long term growth and are not affected by earnings reports
## source: finance.yahoo.com
Thu, 23 Jul 2015 12:03:11 GMT ~ CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/150723/caps8-k.html
*********************************************************
Thu, 23 Jul 2015 12:00:00 GMT ~ Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides
[GlobeNewswire] - TEMPE, Ariz. -- Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced today the conversion of a provisional ...
read full: http://finance.yahoo.com/news/capstone-therapeutics-announces-patent-application-120000212.html
*********************************************************
Mon, 22 Jun 2015 16:53:30 GMT ~ CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
read full: http://biz.yahoo.com/e/150622/caps8-k.html
*********************************************************
Fri, 19 Jun 2015 20:30:00 GMT ~ Capstone Therapeutics Corp. Q1 2015 Operating Update Call scheduled for 4:30 pm ET today
read full: http://biz.yahoo.com/cc/9/144899.html
*********************************************************
Tue, 02 Jun 2015 15:43:03 GMT ~ CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/150602/caps8-k.html
*********************************************************
$CAPS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CAPS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CAPS/company-info
Ticker: $CAPS
OTC Market Place: OTCQB
CIK code: 0000887151
Company name: Capstone Therapeutics Corp
Company website: http://www.capstonethx.com
Incorporated In: DE, USA
Business Description: Capstone Therapeutics Corp. is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions.
$CAPS share structure
## source: otcmarkets.com
Market Value: $8,585,936 a/o Jul 27, 2015
Shares Outstanding: 40,885,411 a/o Mar 13, 2015
Float: Not Available
Authorized Shares: 100,000,000 a/o Mar 13, 2015
Par Value: 0.0005
$CAPS extra dd links
Company name: Capstone Therapeutics Corp
Company website: http://www.capstonethx.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CAPS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CAPS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CAPS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/news - http://finance.yahoo.com/q/h?s=CAPS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CAPS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CAPS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CAPS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Capstone+Therapeutics+Corp&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Capstone+Therapeutics+Corp
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Capstone+Therapeutics+Corp&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.capstonethx.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.capstonethx.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.capstonethx.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CAPS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000887151&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CAPS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CAPS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CAPS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CAPS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CAPS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CAPS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CAPS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CAPS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CAPS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CAPS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CAPS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CAPS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CAPS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CAPS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CAPS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CAPS
$CAPS DD Notes ~ http://www.ddnotesmaker.com/CAPS